Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow YARW by emailGet an email when YARW pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about YARW, unsubscribe in one click. Privacy
📣 What YARW Says Is Next
in 2027 · “This trial is enrolling patients with a confirmed diagnosis of GD who are not receiving ATD treatment or who can discontinue treatment temporarily to participate in the trial, and data are expected in 2027.”
Company press release, Sep 10, 2026 · SEC filing
second half of 2027 · “Data from the Phase 2a portion of the trial are expected in the second half of 2027.”
Company press release, Sep 10, 2026 · SEC filing
2H 2027 · “Data from the Phase 2a portion are expected in 2H 2027.”
Company press release, Jul 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full YARW picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for YARW and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.